Strategic funding Stelexis has secured $43M in Series A funding and is actively expanding its oncology platform, indicating readiness for collaboration, licensing, or co-development opportunities with larger biotechs and contract research organizations seeking access to innovative cancer therapies.

Clinical momentum Positive Phase 1 data for eganelisib in relapsed/refractory AML and higher-risk MDS presented at ASCO 2026 suggests emerging proof of concept and a potential for partnering in late-stage development, clinical trials, or translational research initiatives.

Bioinformatics and tech readiness Stelexis leverages cloud infrastructure (AWS, CloudFront) and modern data practices (JSON-LD) which can be leveraged to propose data management, AI-driven analytics, or high-throughput screening collaborations with data-centric CROs and analytics vendors.

Regional focus and scale potential NY-based, Deerfield-founded profile with mid-sized employee base positions Stelexis as a potential partner for regional manufacturing, scalable GMP services, or strategic alliances with mid-to-large biopharma seeking expansion into oncology portfolios.

Engagement and visibility Active conference presence (ASCO 2026) and public-facing updates create opportunities for sponsorships, joint communications, or advisory partnerships with patient advocacy groups and research consortia to raise awareness and accelerate trial recruitment.